Tumour regression after endostatin therapy

被引：21

作者：

Black, WR ^{[1
]}

Agner, RC

机构：

[1] Rowan Reg Med Ctr, Dept Internal Med, Salisbury, NC 28144 USA

[2] Rowan Reg Med Ctr, Dept Med Oncol, Salisbury, NC 28144 USA

来源：

NATURE | 1998年 / 391卷 / 6666期

关键词：

D O I：

10.1038/35064

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

It was with great interest that we read the report1 on the lack of acquired drug resistance to repeated doses of endostatin in experimental cancers in mice. Of particular interest is the unprecedented finding that each tumour type became indefinitely dormant after a varying number of treatment cycles. We believe one explanation for this phenomenon might be found in the clinical observation that, after complete regression of large bulky tumours, rebiopsy of the primary tumour site will frequently show large amounts of fibrosis or scarring.

引用

页码：450 / 450

页数：1